logo
Hardwire One Health into EU law before ‘Disease X' strikes

Hardwire One Health into EU law before ‘Disease X' strikes

Euractiv09-07-2025
The next pandemic will likely emerge where humans, animals, and ecosystems intersect, yet veterinary systems remain Europe's blind spot.
That warning dominated the 'Preventing Disease X' conference in Brussels on 3 July, where experts called for EU policy to match the scale of the risk.
Their message was clear: if One Health is to be more than a buzzword, it must be hardwired into legislation, now, before Disease X strikes.
Most pandemics, including COVID-19, began with zoonotic pathogens, and the next one, dubbed Disease X, likely will too. Preventing it starts with animal health.
From concept to capability
Dr. Emmanuelle Soubeyran, Director-General of the World Organisation for Animal Health (WOAH), delivered a blunt assessment: 'One Health is not only a concept, but it is becoming a binding principle of global health programmes. But principles are not enough, and they need to be translated into actions, especially when the first signs of disease emerge. That's why veterinary services must be at the frontlines of pandemic prevention.'
She called the COVID-19 pandemic 'a governance stress test that exposed painful gaps in surveillance in the veterinary system and in public health systems and in multi-sectoral coordination.' Those gaps, she warned, still exist.
The problem isn't just technical. It's political.
Soubeyran said: 'We need to raise the profile of animal health and convince both political and private decision-makers that investment in animal health is very important. Animal health is not only an issue of animal health. It has an impact on trade, food security and public health and antimicrobial resistance and also impacts on biodiversity and environmental impact.'
Yet the conversation too often stops at ministries of health. 'Most of the time I speak about One Health in front of ministers of health, but not in front of ministers of agriculture or ministers of economy,' she said. 'I should speak with Ministers of Agriculture, Ministers of Economy, and Ministers of Finance as well.'
Without that broader engagement, she warned, the One Health agenda risks narrowing into 'One Human Health.'
Governance meets the laboratory
Jean-Baptiste Perrin of the European Commission's DG Health Emergency Preparedness and Response Authority (HERA) acknowledged the governance gap, and outlined efforts to fix it. 'We have the preparedness strategy published in March, but additional strategies are coming,' he said.
Chief among them is a new EU stockpiling strategy, due on 8 July. While focused on medical countermeasures (MCMs), it has clear implications for zoonotic outbreaks.
'One is the stockpiling strategy, so explaining how the European stockpile can articulate with national, sometimes regional, or local stockpile for meaningful countermeasures,' Perrin explained.
Also in the pipeline is a strategy for novel countermeasures (NCMs), mapping the full value chain from innovation to deployment.
'One very important point in this strategy … [is] the governance and the coordination, the chain of command that needs to be clear in time of crisis.'
HERA is also working on threat-specific technical roadmaps. 'We're working on threat-specific roadmaps tailored to each pathogen and its most effective countermeasures.'
To support this, HERA is building links between human and veterinary institutes, a concrete expression of the One Health vision.
However, Perrin stressed that none of this will work unless member states collaborate. 'It's a complex task, especially given the differing competencies of Member States.'
Legislative levers remain limited
Asked whether the Critical Medicines Act (CMA) could expand HERA's remit to cover veterinary tools, Perrin acknowledged structural limits. 'There is a specific difficulty at European level to properly and fully implement the One Health approach … we do not have the same competency in public health and animal health. That said, it's worth discussing, and I think we need to keep the discussion open and reflect further on the mandate. But as of today we need to concentrate on human health,' he said.
The price of neglect
If money was missing from the conversation, Professor Jonathan Rushton supplied the spreadsheet.
'Economics is not just for advocacy,' the agricultural economist from the University of Edinburgh warned. 'Economics can help with the drivers of human behaviour … and it can support the assessment of the incentives about how we get people involved in vaccination campaigns.'
Rushton noted that animal health contributes to far more than farm productivity. 'We're providing animals that are healthy; they provide products that are safe to eat, in quantity, that actually provides important micronutrients and proteins … it's also an economic activity.'
Yet global spending still fails to reflect this importance. In a livestock sector worth an estimated $3.3 trillion annually, animal health spending barely reaches 2 percent of that. 'In 2021, $10 trillion was spent on human health. $70 billion was spent on animal health. It's minuscule.'
Prevention is not a luxury
Roxane Feller, Secretary-General of Animal Health Europe, closed the meeting by reinforcing what others had said throughout the day: investment in animal health is strategic. 'Animal health is not a cost, it's an investment.'
Political momentum is growing, she noted, citing a new Parliament report on livestock sustainability, and recent Council debates on vaccination and disease control. But the One Health gap remains.
'The missing elephant in the room is more on One Health. We still believe that there is a lack of understanding of this intrinsic correlation between human, animal and environmental health.'
That disconnect is felt most acutely on the ground.
Emily, a young dairy farmer from South Devon, shared the emotional and financial toll of losing over 130 cows to bovine tuberculosis (TB), wiping out decades of selective breeding and destabilising her entire business and family.
'TB's just not a disease when you're losing cows,' she said. 'It absolutely ruins your life.' Her story underscored what many experts argued throughout the day: that prevention must start with engagement, support, and investment, well before crisis hits.
From silos to systems
What emerged from the conference was not a lack of awareness, but a shared frustration at the fragmentation of the current system.
Governance remains weak, investment lags, and political engagement is too narrow. Surveillance, veterinary services, and pandemic response must be connected through legislation, budgets, and cross-sector cooperation.
As Soubeyran concluded, 'We cannot prevent every outbreak … but with sustained political will, coordinated investment, cross-sectoral action, we can stop the next pandemic, or at least we can get prepared to be more efficient.'
Europe must act before Disease X makes preparation irrelevant.
[Edited By Brian Maguire | Euractiv's Advocacy Lab ]
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Sweden backs EU-wide patent reform to support drug innovation
Sweden backs EU-wide patent reform to support drug innovation

Euractiv

time4 days ago

  • Euractiv

Sweden backs EU-wide patent reform to support drug innovation

Hoping to support pharmaceutical innovation and competitiveness, Stockholm is advocating for a Unitary Patent System. Sweden is one of eleven EU Member States pushing the Danish Presidency to finalise an EU system for enhanced patent protection for medicines. Supplementary Protection Certificates (SPCs) have been in place for several decades in the European Union. They are an intellectual property right that grants a patentholder an additional five years of patent protection, primarily for medicine patents. So far, each Member State has to implement such protection nationally, resulting in varying outcomes between countries. However, a unitary system was proposed by the EU Commission in 2023. Under this proposal, a unitary SPC would be relevant in the 18 EU states that have currently joined the so-called Unitary Patent System. 'A unitary SPC would be an important piece of the puzzle to finalise the Unitary Patent System and a reform that would boost innovation and competitiveness', Louise Petrelius, a senior advisor at the Swedish Ministry of Justice, told Euractiv. She explains that the system is expected to streamline the extension of patent protection for both medicinal and plant protection products (e.g. pesticides) in the EU by introducing a single, unified procedure across participating member states. 'This aims to simplify the current system, which requires separate applications in each country, reducing costs and administrative burden for applicants.' Longer time to market According to Petrelius, SPCs aim to compensate patent holders for the extra time it takes to bring their products to market, due to the compulsory lengthy testing and clinical trials required prior to obtaining regulatory marketing approval. The protection for patents in the EU is 20 years. An SPC could extend such a patent right for a maximum of five years. As the SPC mechanism extends the market exclusivity of a patented medicine beyond the initial patent term, it could delay the entry of generic or biosimilar competition and maintain higher prices for a longer period in the EU. According to the Swedish Intellectual Property Office (PRV), companies producing generics and biosimilars are only allowed to start manufacturing and storing a medicine during the extra five-year protection period if their products are to be exported outside the EU. Civil society organisations, as Médecins Sans Frontières (MSF), have previously called upon the EU to abolish the SPC mechanism, saying it contributes 'to high drug prices and hinders access to essential medicines by delaying the availability of generic and biosimilar alternatives'. No price analysis Johan Pontén, International Coordinator at the Swedish Dental and Pharmaceutical Benefits Agency (TLV), told Euractiv that 'TLV agrees with the Swedish government that a centralised SPC system creates more uniform and simpler management within the EU, which is positive,' adding, however: 'We have not been tasked with analysing how a changed system could affect the prices of medicines and therefore cannot comment on it'. Meanwhile, according to the Swedish Ministry of Justice, there is no ongoing discussion in the EU that links higher prices to the SPC proposal. 'Since the question of the existence of SPCs is not subject to negotiation, it is not discussed in this project. In general, my view is that Sweden is in favour of a system that promotes innovation and attractiveness on the pharmaceutical side, where intellectual property protection is an important component,' Petter Söderbäck, also a senior legal advisor at the Swedish Ministry of Justice, told Euractiv. Euractiv has requested a comment from the Danish Presidency, but has not received a response so far. [Edited by Vasiliki Angouridi]

Last-resort antibiotic excluded from Belgian system, testing EU pharma reforms
Last-resort antibiotic excluded from Belgian system, testing EU pharma reforms

Euractiv

time5 days ago

  • Euractiv

Last-resort antibiotic excluded from Belgian system, testing EU pharma reforms

A critical antibiotic designed to treat infections caused by multidrug-resistant bacteria will remain unavailable through Belgium's reimbursement system after negotiations between the government and the manufacturer failed. The problem goes far beyond Belgium. The inability to secure access to cefiderocol reflects a broader European market failure in valuing and funding last-resort antibiotics. 'The fight against antimicrobial resistance (AMR) is a spearhead of your policy and was a priority during the recent Belgian EU presidency,' MP Irina De Knop (Open VLD) told Health Minister Frank Vandenbroucke in the Belgian Parliament on 15 July, addressing the issue. 'The challenge lies not only in preventing resistance but also in ensuring access to scarce, new antibiotics that serve as last-resort treatments.' First-in-class antibiotic Cefiderocol is not a generic antibiotic. It is a first-in-class, patented siderophore cephalosporin developed by Shionogi, approved in the EU in 2020 under the name Fetcroja®. Specifically engineered to treat carbapenem-resistant Gram-negative bacteria such as Acinetobacter baumannii and Pseudomonas aeruginosa , it penetrates bacterial defences by hijacking iron uptake pathways. Its novel mechanism and limited target population make it difficult to assess using traditional volume-based pricing and reimbursement models designed for high-volume generics. Cefiderocol targets 'superbugs' identified by the World Health Organisation (WHO) as priority pathogens and is intended for an estimated 200 patients per year in Belgium, typically those with no remaining treatment options. 'Precisely because of this limited target group, it is hardly commercially viable,' said De Knop. 'The societal value of reserve antibiotics lies not in frequent use, but in their availability. This leads to a 'broken market' that threatens innovation and sustainable access.' Cost and safety criteria Minister Vandenbroucke confirmed that Belgium's reimbursement process for cefiderocol ended without a deal. 'We went far to reach an agreement, especially for those 55 patients,' he said. 'But apparently, even with far-reaching proposals, we could not meet the company's demands. The requested price is more than double that of the most expensive reimbursed late-line antibiotic.' Citing limited clinical evidence and safety concerns from one comparative trial, the minister explained that the antibiotic is classified as a true last-line option and must be kept outside the hospital's regular reimbursement system due to its high cost. 'In the absence of strict prescription controls, there's a risk it would be used too broadly, potentially accelerating resistance to this last-resort treatment,' he warned. While Belgium is monitoring EU-level initiatives, including push and pull incentives and alternative financing mechanisms, the minister acknowledged: 'There are currently no concrete plans to introduce a subscription financing model like in the United Kingdom.' Company calls for pan-European rethink The product's manufacturer, Shionogi, told Euractiv that Belgium's decision reflects a systemic issue across Europe. 'Reserve antibiotics play a vital role in treating infections caused by multidrug-resistant (MDR) pathogens, often when no other options remain,' the company said. 'Although used in very small patient populations, these antibiotics offer immense public health value, yet current reimbursement systems are not designed for low-volume, high-importance medicines.' The company cited remarks made by Minister Vandenbroucke during an AMR conference held under the Belgian Presidency of the Council in June 2024: 'Look at antibiotics: they should not be used too much. However, some of them have to be ready as soon as you need them. For that, you need a different kind of financing, almost like a subscription to a streaming service.' 'These initiatives, including the 'streaming service' model referenced by Minister Vandenbroucke, are aligned with G7 health priorities and show how sustainable innovation and access can go hand in hand,' the company said. Shionogi confirmed participation in delinked funding pilots: 'Yes. Shionogi is actively participating in the UK's NHS AMR Subscription Model, which pays for antibiotics based on their value to the health system, not the volume used. We were also involved in Sweden's national pilot and are engaged in discussions with HERA on similar approaches.' 'We recognise that European countries have unique needs. In Belgium, as across Europe, we're always open to solutions that deliver timely access for patients, reward responsible use, and make continued innovation in antibiotics possible,' the company's CEO Huw Tippett told Euractiv. A test case for the EU's Pharmaceutical Package Despite Belgium's efforts to strike a deal, MP De Knop warned that the lack of reimbursement leaves patients at risk. 'The result remains that this antibiotic, which is particularly important for a small group of people, is currently not reimbursed,' she said. 'You also did not present an immediate solution,' pointing to the minister. Belgium plans to introduce 'early and fast access' procedures by 2026, but currently lacks a dedicated funding stream for reserve antimicrobials. With no viable market and limited public procurement tools, cefiderocol has become a test case for Europe's broader pharmaceutical policy agenda. Antibiotic incentives are central to the EU's Pharmaceutical Package, currently under negotiation. The European Commission has proposed transferable exclusivity vouchers and pull incentives to stimulate antimicrobial innovation, though these remain politically contentious. Under the Belgian Council Presidency in June 2024, EU health ministers adopted Council conclusions calling on the European Commission and Member States to 'explore alternative reimbursement models, such as subscription-based schemes,' and to strengthen 'EU-level coordination to ensure sustainable access to critical antimicrobials.' These conclusions were part of the strategy paper 'The Future of the European Health Union: a Europe that cares, prepares and protects.' While often associated with generic shortages, the proposed Critical Medicines Act also introduces tools such as joint procurement, strategic stockpiling, and EU-wide demand coordination, all of which could be applicable to patented, last-resort antibiotics like cefiderocol. [Edited by Vasiliki Angouridi]

Mounting pressure on Sweden over Gaza medevac refusals
Mounting pressure on Sweden over Gaza medevac refusals

Euractiv

time04-08-2025

  • Euractiv

Mounting pressure on Sweden over Gaza medevac refusals

The Swedish government is facing increased pressure to admit wounded Palestinian patients, having consistently refused to assist with medical evacuation from the Gaza Strip. The centre-right coalition government, composed of Moderates, Liberals, and Christian Democrats, is arguing that Sweden already supports Egyptian healthcare with medical equipment and also supports UN bodies, such as UNICEF and UNFPA, by providing healthcare and humanitarian support on the ground. "The government does not rule out, as other countries do, accepting patients for care in Sweden as a complement to on-site assistance. In each case, consideration must be given to the circumstances, what solutions will provide the fastest help to those in need, and also how we can best help as many people as possible. In the current context, it is crucial to ensure that people receive immediate help where they are," Acko Ankarberg Johansson, the Christian Democrat Health Minister, told Euractiv. Agency on standby Magdalena Tham Lindell, head of humanitarian operations at the Swedish Civil Contingencies Agency (MSB), told Euractiv that the agency has so far had to turn down 37 requests from the EU Civil Protection Mechanism for the medical evacuation of trauma patients from Gaza since the conflict between Hamas and Israel began. "We do not have any mission from the Swedish government to carry out such a task," she added. However, Tham Lindell also said that the Civil Contingencies Agency is ready to carry out medical transport of patients from Gaza to Sweden. "Yes, we are well prepared to do this if we receive such a mission," she said. As early as 2023, the acting EU Commissioners, Stella Kyriakides and Janez Lenarčič, urged member states to provide care to patients from Gaza. The UN and the WHO have also been calling for assistance and support. Pressure on Sweden Despite an EU-wide slow reaction, 14 EU countries, including Italy, Romania, and Spain, are currently assisting with medical evacuations from Gaza, according to the EU mechanism. With the situation deteriorating into a worst-case scenario involving widespread hospital destruction, starvation and the killing of civilians by the Israeli side, calls for the evacuation of wounded children and adults have grown louder and more frequent in Sweden. Stakeholders, including the Swedish Association of Health Professionals (the union representing nurses and midwives), doctors, hospitals, and private care providers, have requested that ministers revise their position. The Hospital Doctors Association has recently reiterated its request to allow Gaza patients admission into Sweden in an open letter to the government. "We are dismayed that despite the readiness of healthcare providers, the Swedish government is refusing to accept patients from Gaza," the association's board wrote. Parliamentary pressure Daniel Helldén, one of the Swedish Green Party's two spokespersons, also formally asked Ulf Kristersson, the Swedish Prime Minister, what would make the government change its mind on the issue. "We have individual regions, hospitals and doctors who want to help. Many other countries have helped. Doctors who have been on the ground say that their resources are not enough while the killing continues. I can't for the life of me understand why the government is saying no to this," he told Dagens Nyheter. Fredrik Lundh Sammeli, Health Spokesperson and a Parliamentarian for the Social Democrats, the Swedish main opposition party, recently asked on Facebook: "How long will the government stand by while children die?" If the Swedish Parliament had been open, he wrote, he would already have called the Minister for Health to the Social Affairs Committee to answer: "Why does Sweden refuse to accept injured children from Gaza, when other European countries do?" Passive stance Lundh Sammeli also told Euractiv that the party considers that the government has taken a far too passive position on the Gaza issue. "This is sad. Sweden should be committed to assisting people in need during humanitarian disasters and conflicts. We have received seriously injured people from Ukraine and should have the same attitude to the Gaza war as part of the coordinated European effort." He insisted that on-the-spot help and transporting seriously injured people to Swedish hospitals are not mutually exclusive. Sweden has so far received and treated 237 patients from Ukraine since the Russian full-scale invasion in 2022, Johan Köhler, Programme Manager at the National and Civil Protection Operations Section of the MSB, told Euractiv. According to the BBC and the Sunday Times, the UK government now plans to evacuate up to 300 seriously ill or wounded children from Gaza. The plan could be set into action within weeks. A private initiative has already brought Palestinian children from Gaza to the UK. [Edited by Vasiliki Angouridi]

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store